Y-27632 dihydrochloride: Selective ROCK Inhibitor for Cytoskeletal and Cancer Research

Executive Summary:
Y-27632 dihydrochloride is a small-molecule inhibitor that selectively targets Rho-associated protein kinases, ROCK1 and ROCK2, with IC50 values of approximately 140 nM and Ki of 300 nM, respectively (APExBIO). It exhibits >200-fold selectivity over related kinases, including PKC and MLCK. Y-27632 dihydrochloride disrupts Rho-mediated stress fiber formation, modulates cell cycle progression, and suppresses tumor invasion in vitro and in vivo (Pereira et al. 2025). The compound is highly soluble in DMSO, ethanol, and water, and is compatible with routine laboratory workflows. It is supplied by APExBIO (SKU A3008) as a desiccated solid for research use only.

Biological Rationale

ROCK1 and ROCK2 are serine/threonine kinases that act downstream of the RhoA GTPase. They regulate actin cytoskeletal dynamics, cell polarity, migration, contraction, and cell cycle progression. Dysregulation of Rho/ROCK signaling is implicated in cancer cell invasion, metastasis, and neurodevelopmental disorders (Pereira et al. 2025). Inhibition of ROCKs alters stress fiber formation and cytokinesis, providing a mechanistic basis for studies on cytoskeletal modulation, stem cell viability, and tumor biology. Y-27632 dihydrochloride is thus utilized as a tool compound to dissect these pathways and to improve the reproducibility of cell-based assays (Y-27632 A3008 Data-Driven Solution).

Mechanism of Action of Y-27632 dihydrochloride

Y-27632 dihydrochloride competitively inhibits the ATP-binding catalytic domains of ROCK1 and ROCK2. Its IC50 for ROCK1 is approximately 140 nM, and Ki for ROCK2 is 300 nM (APExBIO). Inhibition is highly selective, with >200-fold specificity relative to PKC, PKA, MLCK, and PAK. Y-27632 blocks Rho-mediated phosphorylation of downstream targets such as myosin light chain (MLC), leading to disruption of actin-myosin contractility and loss of stress fibers (Y-27632 Advanced Cytoskeletal Research). It interferes with cell cycle progression from G1 to S phase and suppresses cytokinesis by preventing contractile ring formation.

Evidence & Benchmarks

• Y-27632 dihydrochloride reduces Rho-mediated actin stress fiber formation in fibroblasts at 10 μM within 30 minutes (Pereira et al. 2025).
• In vitro, the compound decreases proliferation of prostatic smooth muscle cells in a concentration-dependent manner (1–30 μM, 24–72 hours) (APExBIO).
• Y-27632 dihydrochloride enhances survival of dissociated human embryonic stem cells during passaging at 10 μM, improving colony formation rates by >30% (Y-27632 Advanced Cytoskeletal Research).
• In mouse xenograft models, treatment with 30 mg/kg Y-27632 dihydrochloride (intraperitoneal, daily) reduces tumor invasion and metastasis by up to 50% over 21 days (Pereira et al. 2025).
• Solubility parameters: ≥111.2 mg/mL in DMSO, ≥17.57 mg/mL in ethanol, ≥52.9 mg/mL in water at 25°C; stock solutions stable below –20°C for several months (APExBIO).

Applications, Limits & Misconceptions

Y-27632 dihydrochloride is used to investigate:

• Cell-permeable ROCK inhibition for cytoskeletal studies
• Enhancement of stem cell viability and colony formation
• Suppression of tumor cell invasion, migration, and metastasis
• Modulation of Rho/ROCK signaling in disease models
• Optimization of cell proliferation and cytotoxicity assays for workflow reproducibility (Y-27632 A3008 Data-Driven Solution): This article clarifies the specific solubility and storage guidelines that were only briefly mentioned in the linked resource.
• Advanced 3D organoid and cancer metastasis models (Y-27632 in 3D Organoid Technology): This article extends previous work by specifying in vivo dose-response benchmarks and selectivity data.

Common Pitfalls or Misconceptions

• Y-27632 dihydrochloride does not inhibit upstream RhoA activation or other Rho family GTPases; it is selective for ROCK1/2 catalytic domains.
• High concentrations (>50 μM) may induce off-target effects in certain cell types; always titrate dose for each model system.
• Long-term storage of aqueous solutions (>1 week) leads to decreased potency; prepare fresh working solutions as recommended (APExBIO).
• Use of Y-27632 dihydrochloride does not compensate for genetic deficiencies in cytoskeletal regulators such as YY1, but may be used to probe pathway interactions (Pereira et al. 2025).
• It is not a general anti-proliferative agent; effects are context- and cell-type-specific.

Workflow Integration & Parameters

Y-27632 dihydrochloride (APExBIO, SKU A3008) is supplied as a dry, desiccated powder. For in vitro use, dissolve in DMSO to prepare a 10–100 mM stock solution (e.g., 111.2 mg/mL in DMSO at 25°C). Warm to 37°C or use ultrasonic bath to enhance solubility. Store aliquots below –20°C, protected from light and moisture. For working concentrations, dilute stocks in culture medium immediately before use.

Recommended concentrations:

• Cell proliferation, viability, and cytoskeletal assays: 5–20 μM
• Stem cell colony formation: 10 μM during passaging
• In vivo mouse models: 10–30 mg/kg/day, intraperitoneal injection

Y-27632 dihydrochloride is compatible with standard cell lines, primary cultures, and organoid systems (Precision ROCK Inhibition for Cytoskeleton): This resource is updated here with expanded solubility and storage data for workflow optimization.

Conclusion & Outlook

Y-27632 dihydrochloride is a validated, highly selective ROCK inhibitor that has transformed research in cytoskeletal biology, stem cell maintenance, and cancer invasion. Its reproducible activity profile, robust solubility, and specificity make it an essential tool for dissecting Rho/ROCK signaling. Ongoing studies continue to reveal the pivotal role of ROCK pathways in neurodevelopmental and oncogenic processes, supporting the strategic use of Y-27632 dihydrochloride in translational research (Strategic ROCK Inhibition). For detailed protocols and ordering information, refer to the APExBIO Y-27632 dihydrochloride product page.